BofA raised the firm’s price target on Liquidia to $15 from $13 and keeps a Buy rating on the shares. The firm noted Liquidia was trading with strength during the session after the announcement of a positive legal resolution regarding the ‘793 patent after the recent appeal, which clears a path for the full approval and launch of Yutrepia in pulmonary arterial hypertension. The firm noted that Liquidia is primed for a full approval and launch of Yutrepia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LQDA:
- U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
- Liquidia director Manning buys 279,330 common shares
- Liquidia prices 3.49M shares at $7.16 in underwritten public offering
- Liquidia Announces Pricing of Public Offering of Common Stock
- Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update